5,659 AbbVie Inc. $ABBV Shares Sold by MRA Advisory Group

MRA Advisory Group trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 71.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,224 shares of the company’s stock after selling 5,659 shares during the quarter. MRA Advisory Group’s holdings in AbbVie were worth $582,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at about $30,000. Abound Financial LLC bought a new position in shares of AbbVie in the 4th quarter valued at approximately $32,000. Merkkuri Wealth Advisors LLC acquired a new stake in AbbVie in the 1st quarter worth approximately $34,000. Marquette Asset Management LLC lifted its holdings in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the last quarter. Finally, Phillip James Consulting Co. bought a new stake in AbbVie during the fourth quarter worth approximately $36,000. 70.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on ABBV. UBS Group reiterated a “neutral” rating on shares of AbbVie in a report on Tuesday. Leerink Partners upped their price objective on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Barclays lifted their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Morgan Stanley upped their price target on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $274.32.

AbbVie Price Performance

ABBV stock traded up $6.97 on Wednesday, reaching $273.66. 2,122,512 shares of the company were exchanged, compared to its average volume of 6,413,482. The firm has a market capitalization of $483.50 billion, a PE ratio of 77.32, a PEG ratio of 1.20 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $274.94. The stock’s fifty day moving average price is $258.12 and its 200 day moving average price is $235.42.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Major lymphoma trial success: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The Phase 3 EPCORE DLBCL-2 study achieved its progression-free-survival goal, potentially positioning Epkinly as a frontline treatment competitor to Roche’s Polivy. The companies plan to discuss the results with regulators. AbbVie and Genmab announce positive EPCORE DLBCL-2 results
• Positive Sentiment: Two FDA breakthrough designations: The FDA granted Temab-A (telisotuzumab adizutecan, or ABBV-400) Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate regulatory interactions and improve the commercial outlook for AbbVie’s antibody-drug-conjugate pipeline. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Higher valuation support: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating. The target increase reflects confidence in the company’s pipeline and earnings durability.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter results later this month, which could provide additional evidence on operating performance and the company’s post-Humira growth strategy.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie included $216 million of acquired in-process research and development and milestone expenses in its third-quarter outlook, resulting in EPS guidance of $3.73–$3.77 versus the prior consensus estimate of approximately $3.85. Full-year adjusted EPS guidance was also reduced.
• Negative Sentiment: Dividend sustainability concerns: Recent commentary highlighted a reported payout ratio above 190%, raising questions about how comfortably current earnings cover the dividend. This could limit enthusiasm among income-focused investors despite AbbVie’s strong pipeline news.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.